URMC / Research / Clinical Trials / Study Details ILEU18011 / Kristen O'DwyerResearch Question:What is the safety and effectiveness of APTO-253 for the treatment of patients with the condition of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) for which either the standard treatment has failed, is no longer effective, or can no longer be administered safely or poses a risk for your general well being?Basic Study Information Purpose:This study is being done to evaluate the safety and effectiveness of APTO-253 for the treatment of patients with the condition of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) for which either the standard treatment has failed, is no longer effective, or can no longer be administered safely or poses a risk for your general well being. Location: University of Rochester Medical CenterStudy Reference #: ILEU18011Lead Researcher (Principal Investigator) Lead Researcher: Kristen O'Dwyer Study Contact InformationStudy Coordinator: Amber JohnsonEmail: amber_johnson@urmc.rochester.edu Additional Study Details URMC / Wilmot Cancer Institute /Research / Clinical Trials / Study Details Trial Not Found The study you are looking for is not active at this time. Return to Search